Tagraxofusp + Azacitidine for AML and MDS
Trial Summary
The trial information does not specify if you need to stop taking your current medications. However, it mentions that you should not have uncontrolled illnesses or be on certain investigational agents recently. It's best to discuss your specific medications with the study team.
Research shows that Azacitidine, a component of the treatment, is effective in improving survival for patients with higher-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It is well-tolerated and has been shown to prolong overall survival compared to conventional care regimens, making it a recommended first-line treatment for these conditions.
12345Azacitidine, used for conditions like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), has a favorable safety profile with common side effects including nausea, vomiting, and low blood cell counts. There is no specific safety data available for the combination of Tagraxofusp and Azacitidine, but Azacitidine alone is generally considered safe in humans.
678910The combination of Tagraxofusp and Azacitidine is unique because it targets CD123, a protein found on most acute myeloid leukemia (AML) cells, and uses a novel mechanism involving a diphtheria toxin to attack these cells. This approach is different from traditional chemotherapy and shows promise in treating high-risk AML, including cases with specific genetic mutations.
56111213Eligibility Criteria
This trial is for patients with CD123 positive acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have undergone a donor hematopoietic cell transplant. The study aims to find out if maintenance therapy with Tagraxofusp and Azacitidine can prevent cancer from returning.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Acute myeloid leukemia
- Chronic myelomonocytic leukemia
- Myelodysplastic syndromes
- Myelodysplastic syndromes
- Chronic myelomonocytic leukemia
- Myelodysplastic syndromes
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Acute myeloid leukemia